Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE – Get a rating) received a consensus rating of “moderate buy” by the fourteen research companies that currently cover the business, Marketbeat reports. One financial analyst gave the stock a sell rating, one issued a hold rating and seven issued a buy rating for the company. The 12-month average price target among brokerages that have covered the stock over the past year is $111.58.
RARE has been the subject of several analyst reports. Piper Sandler lowered her price target on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a Thursday, July 28 research note. Evercore ISI lowered its price target on shares of Ultragenyx Pharmaceutical to $60.00 in a Tuesday, August 9 research note. Goldman Sachs Group lowered its price target on shares of Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating on the stock in a Tuesday, May 24 research note. StockNews.com downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a Tuesday, June 21 research note. Finally, Citigroup lowered its price target on shares of Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, Aug. 3 research note.
Ultragenyx Pharmaceutical Price Performance
RARE opened at $49.24 on Monday. The company’s 50-day simple moving average is $53.60 and its two-hundred-day simple moving average is $59.89. Ultragenyx Pharmaceutical has a 1-year low of $45.20 and a 1-year high of $103.14. The company has a market capitalization of $3.45 billion, a price-earnings ratio of -6.73 and a beta of 1.23.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last released its quarterly results on Thursday, July 28. The biopharmaceutical company reported ($2.26) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company posted revenue of $89.34 million for the quarter, versus $87.33 million expected by analysts. During the same period of the previous year, the company posted ($1.45) EPS. The company’s quarterly revenue increased 2.7% from the same quarter last year. On average, stock analysts expect Ultranyx Pharmaceutical to post earnings per share of -7.79 for the current fiscal year.
Ultragenyx Pharmaceutical Institutional Trading
Several large investors have recently changed their holdings in RARE. State Street Corp increased its stake in shares of Ultragenyx Pharmaceutical by 26.1% during the second quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company valued at $146,603,000 after purchasing an additional 508,624 shares during the period. Wellington Management Group LLP increased its stake in shares of Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company valued at $244,747,000 after purchasing an additional 492,842 shares during the period. Suvretta Capital Management LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth approximately $40,804,000. Goldman Sachs Group Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 43.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 725,678 shares of the biopharmaceutical company valued at $61,023,000 after purchasing an additional 219,470 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Ultragenyx Pharmaceutical by 682.3% during the fourth quarter. Marshall Wace LLP now owns 234,230 shares of the biopharmaceutical company valued at $19,697,000 after purchasing an additional 204,288 shares during the period. 88.27% of the shares are currently held by institutional investors and hedge funds.
About Ultranyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here